MGMT and central nervous system cancer: The clinical application of assessing the methylation status of the MGMT gene promoter in gliomas, which indicates tumor response to temozolomide chemotherapy and patient prognosis, has been successful.556,557 Unfortunately, this application is based on tumor tissue-derived MGMT gene promoter methylation status, with no mature clinical studies on circulating tumor DNA.